Live feed06:30:00·792dPRReleasevia QuantisnowSavara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)ByQuantisnow·Wall Street's wire, on your screen.SVRA· Savara Inc.Health Care
